Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Indium-111 is a radioactive isotope of indium that decays by electron capture to stable cadmium-111 with a physical half-life of approximately 2.8 days (67.2 hours)[1][4][9][10]. It emits gamma photons at energies of 171 keV and 245 keV, making it suitable for detection through gamma cameras and SPECT imaging[1][4][5][9]. Indium-111 is not a biological target (such as a receptor, enzyme, or transporter) but is a radioisotope used as a diagnostic tracer in nuclear medicine. It is commonly used to label biological molecules, cells, antibodies, or peptides for imaging the localization of tumors (e.g., indium-111 pentetreotide for neuroendocrine tumors), sites of infection, or inflammation (e.g., indium-111-labeled leukocytes)[5][6][7]. As such, "Indium-111 decay emission tracer" is not a canonical biological target, but rather the radioisotope component of diagnostic radiopharmaceuticals. It does not have intrinsic biological function or act as a "therapeutic target"[1][6][7][9]. Summary of errors/limitations in the target name "Indium-111 decay emission tracer": - It is not a therapeutic target, but a radioactive tracer (false positive as a target)[1][7]. - It is properly referred to as "Indium-111" or "111In" in the context of radiopharmaceuticals[1][6][7]. - Its function, safety, and disease associations depend on the ligand or construct to which it is attached (e.g., octreotide, antibodies, leukocytes)[5][6][7]. - No canonical therapeutic drugs "interact" with indium-111 as a target; instead, drugs or biomolecules are labeled with it for imaging[7]. - Molecular classification is "Other" (radioisotope), not receptor, enzyme, transporter, etc. If you are seeking information on a nuclear medicine imaging tracer labeled with indium-111 (such as "indium-111 pentetreotide" or "indium-111 chloride-labeled leukocytes"), you should specify the biomolecule or target rather than the decay emission tracer itself. Indium-111 is an imaging tool, not a molecular therapeutic target[1][5][6][7][9].
*Not applicable*; indium-111 acts as a gamma-emitting radioisotope detected in radiopharmaceuticals[1][6][7] - Mechanism depends on the compound it labels (e.g., binds somatostatin receptor in case of 111In-pentetreotide[6])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Indium-111 (111In).